Search

Your search keyword '"Obara, Wataru"' showing total 773 results

Search Constraints

Start Over You searched for: Author "Obara, Wataru" Remove constraint Author: "Obara, Wataru" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
773 results on '"Obara, Wataru"'

Search Results

5. Quantification of escape from X chromosome inactivation with single-cell omics data reveals heterogeneity across cell types and tissues

6. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial

9. Genetic Risk Stratification of Primary Open-Angle Glaucoma in Japanese Individuals

11. Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.

14. PD61-11 INITIAL EXPERIENCE OF ROBOT-ASSISTED RADICAL PROSTATECTOMY USING HINOTORI SURGICAL ROBOT SYSTEM

16. PD41-06 EVALUATION OF THE TUMOR MICROENVIRONMENT OF UPPER TRACT UROTHELIAL CARCINOMA USING MULTIPLEX FLUORESCENCE IMMUNOHISTOCHEMISTRY

17. MP05-19 POLYGENETIC RISK SCORE FOR PROSTATE CANCER IS ASSOCIATED WITH LIPOPOLYSACCHARIDE PATHWAY IN GUT MICROBIOME

19. Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi‑institutional retrospective study

21. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study

22. Emphysematous pyelonephritis diagnosed by acute changes detected via computed tomography: A case report.

23. Supplementary Tables S1-S5 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

24. Data from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

25. Supplementary Legends from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

26. Supplementary Figure S1 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

27. WCN24-244 The utility of Indoxyl sulfate as a biomarker for early detection of CKD

28. WCN24-866 THE TYPE OF HEPARIN USED FOR ANTICOAGULATION IN PATIENTS ON HEMODIALYSIS AFFECTS CARNITINE METABOLISM

29. Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era

30. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

31. Common and rare genetic variants predisposing females to unexplained recurrent pregnancy loss.

32. Comparison of outcomes in kidney transplantations involving blood-related and non-blood-related living donors: a multicenter retrospective study by the Michinoku renal transplant network.

34. Abnormal carnitine metabolism in hemodialysis patients on different anticoagulants.

35. Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC

36. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

39. Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancer

41. A case of complete response to avelumab plus axitinib combination therapy for metastatic clear cell renal cell carcinoma in a kidney undergoing dialysis

44. Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma

46. TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

50. Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases

Catalog

Books, media, physical & digital resources